Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28130121 | 0.82 | ALDH1A1 (0.55) | CYP2C9CYP2C19CYP3A4HTTHDAC1 | |
| SCHEMBL12841358 | 0.79 | TSHR (0.70) | CYP2C9CYP2C19CYP3A4GAALMNA | |
| SCHEMBL3221999 | 0.79 | HPGDS (0.55) | CYP3A4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL6598806 | 0.77 | TSHR (0.53) | CYP2C9CYP2C19CYP3A4HTTHDAC3 | |
| SCHEMBL9713098 | 0.72 | CYP3A4 (0.49) | CYP2C9CYP2C19CYP3A4HTTHDAC3 | |
| Benzohydroxamate SCHEMBL11883624 | 0.72 | HDAC8 (0.95) | HDAC3CA12CA1IDO1ALOX15 | |
| SCHEMBL17714580 | 0.71 | CYP3A4 (0.52) | CYP2C9CYP2C19CYP3A4HTTHDAC3 | |
| SCHEMBL2399935 | 0.71 | HTT (0.96) | CYP2C9CYP2C19CYP3A4HTTHDAC8 | |
| SCHEMBL3824146 | 0.71 | HTT (0.56) | CYP2C9CYP2C19CYP3A4HTTHDAC3 | |
| SCHEMBL2462957 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655257-A | ASH1L inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2020-09-11 | — | — | CN | disclosed |
| CN-111542318-A | ASH1L degradants and methods of treatment therewith | 密歇根大学董事会 | 2020-08-14 | — | — | CN | disclosed |
| US-20130096334-A1 | Magnetic Nanoparticle-Supported Glutathione as a Sustainable Organocatalyst | The United States of America as represented by the Administrator of the United States Environment Pr (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096334-A1 | Magnetic Nanoparticle-Supported Glutathione as a Sustainable Organocatalyst | The United States of America as represented by the Administrator of the United States Environment Pr (US) | 2013-04-18 | — | — | US | disclosed |
| US-8324125-B2 | Magnetic nanoparticle-supported glutathione as a sustainable organocatalyst | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324125-B2 | Magnetic nanoparticle-supported glutathione as a sustainable organocatalyst | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110054180-A1 | Magnetic Nanoparticle-Supported Glutathione as a Sustainable Organocatalyst | USA as Represented by the Administrator of U.S. Environmental Protection Agency (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110054180-A1 | Magnetic Nanoparticle-Supported Glutathione as a Sustainable Organocatalyst | USA as Represented by the Administrator of U.S. Environmental Protection Agency (US) | 2011-03-03 | — | — | US | disclosed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044194-A2 | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005041879-A2 | COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054180-A1 | Magnetic Nanoparticle-Supported Glutathione as a Sustainable Organocatalyst | GSTK1, GSTA1, GSTP1 | CYP2C9 1774/4885CYP2C19 1576/4885CYP3A4 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.